Research programme: mitosis inhibitors - Cyclacel

Drug Profile

Research programme: mitosis inhibitors - Cyclacel

Alternative Names: Mitosis inhibitors research programme - Cyclacel

Latest Information Update: 02 Apr 2008

Price : $50

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Class
  • Mechanism of Action Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 02 Apr 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 28 Mar 2006 Xcyte Therapies has merged with Cyclacel to form Cyclacel Pharmaceuticals
  • 16 Mar 2005 Cyclacel and Altana Pharma AG executed a research collaboration agreement on mitotic target identification
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top